April 17, 2017
Cashing Out: How Big Pharma Continues to Capitalize on the Antitrust Loophole Created in FTC v. Actavis
The drug industry is one of the most lucrative in the United States. Drug manufacturers routinely find themselves thrust into patent infringement litigation against generic manufacturers who are motivated by high potential returns from the marketplace. In lieu of expensive and time-consuming litigation, brand and generic manufacturers will often enter into settlement agreements; however, these agreements are frequently wrought with anticompetitive effects−commonly known in the industry as “reverse payment settlements.” In 2013, the Supreme Court was asked to determine if reverse payment settlements were violations of antitrust law, but it only addressed one type of settlement, opening the door for continued antitrust violations and lower court confusion. This Recent Development will examine the different forms of reverse-payment settlements, the Supreme Court’s silence, and why this issue continues to plague circuit courts around the nation.
Laura A. Gregory, Cashing Out: How Big Pharma Continues to Capitalize on the Antitrust Loophole Created in FTC v. Actavis, 18 N.C.J.L. & Tech. On. 107 (2016), http://ncjolt.org/wp-content/uploads/2016/12/Gregory_Final-.pdf.
The North Carolina Journal of Law & Technology has adopted the Open Access Program, a part of the Scholar’s Copyright Project created by Science Commons. Authors designate the conditions under which their articles are licensed. By downloading articles, you agree to comply with the license terms specified. Please contact NC JOLT at email@example.com with permissions inquiries.